课题基金 / 基金详情

Microbiota Specific T Cell Selection

Microbiota Specific T Cell Selection
微生物群特异性 T 细胞选择
批准号:
10532220
负责人:
Matthew Bettini
金额:
$34.14万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-12-03 至 2024-11-30

项目摘要

项目成果

Matthew Bettini的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Over the millennia humans have coevolved with a large number of microorganisms, collectively known as the microbiota, which provide many key signals that aid in the development and proper functioning of the immune system. It is vital to human health that the immune system remains tolerant to the microbiota maintaining a symbiotic relationship. To limit pathological immune responses against the microbiota, immune tolerance to the microbiota must be established early in life. A breakdown in tolerance to commensal microbes can result in chronic inflammatory disorders such as inflammatory bowel disease, asthma and dermatitis. Homeostasis with the microbiota is achieved by generation of antigen specific regulatory T cells that develop in both the thymus and periphery. Exposure to the microbiota, especially during the neonatal period is thought to be critical for this Treg induction. It has been found in humans as well as in animal models of disease, that compositional changes in the microbiota, also known as dysbiosis, correlate with increased susceptibility to subsequent induction of inflammatory disease. Notably, changes early in life are thought to have the most significant impact on disease susceptibility. In animal models, colonization with select intestinal microbes sensitizes to disease. It remains unclear how tolerance against the microbiota is achieved, and further, if the ability to induce tolerance to intestinal microbes is limited to a specific early life developmental window. Using a mouse model whose T cell receptor recognizes intestinal microbes, we find intestinal colonization with this microbe leads to selection of T cells specific for that organism. We hypothesize that intestinal antigen presenting cells (APCs) that encounter these organisms traffic to the thymus where they induce T cell selection. In Aim 1 of the proposed work, we will use in vivo models to define how introduction of specific microbes leads to alterations of T cell populations. We will also define whether there are differential impacts on T cell development depending on the developmental window of when microbial colonization occurs. We will further define if timing of colonization with select microbes promotes or limits development of inflammatory disease. In Aim 2 we will define how the microbe or microbial product travels from the intestine to the thymus. We will determine the intestinal cell population required for trafficking of this microbe as well as define transcriptional profiles that allow for T cell selection. This will identify pathways that we will be able to manipulate to limit or rescue from the development of autoimmunity.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/s41586-021-03531-1
发表时间: 2021-06
期刊: Nature
影响因子: 64.8
作者: [Zegarra-Ruiz DF, Kim DV, Norwood K, Kim M, Wu WH, Saldana-Morales FB, Hill AA, Majumdar S, Orozco S, Bell R, Round JL, Longman RS, Egawa T, Bettini ML, Diehl GE]
通讯作者: Diehl GE
DOI: 10.3389/fimmu.2022.974178
发表时间: 2022
期刊: Frontiers in immunology
影响因子: 7.3
作者: []
通讯作者:
Early-life microbiota-immune homeostasis.
早期生命微生物群 - 免疫稳态。
DOI: 10.3389/fimmu.2023.1266876
发表时间: 2023
期刊: FRONTIERS IN IMMUNOLOGY
影响因子: 7.3
作者: [Reynolds, Hayley M., Bettini, Matthew L.]
通讯作者: Bettini, Matthew L.
Early life regulation of microbiota specific thymic T cell development
  • 批准号:
    10568756
  • 项目类别:
  • 资助金额:
    $82.97万
  • 财政年份:
    2022
  • 负责人:
    Matthew Bettini
  • 依托单位:
Self-Reactive T Cell Development in Type 1 Diabetes
  • 批准号:
    10413081
  • 项目类别:
  • 资助金额:
    $38.13万
  • 财政年份:
    2019
  • 负责人:
    Matthew Bettini
  • 依托单位:
Self-Reactive T Cell Development in Type 1 Diabetes
  • 批准号:
    10026565
  • 项目类别:
  • 资助金额:
    $38.13万
  • 财政年份:
    2019
  • 负责人:
    Matthew Bettini
  • 依托单位:
Microbiota Specific T Cell Selection
  • 批准号:
    10308400
  • 项目类别:
  • 资助金额:
    $34.24万
  • 财政年份:
    2018
  • 负责人:
    Matthew Bettini
  • 依托单位:
海外基金